SHORT COMMUNICATION

Serum zonulin as an index of glucose dysregulation in children and adolescents with overweight and obesity

Francesca Olivieri | Alice Maguolo | Massimiliano Corradi | Chiara Zusi | Valentina Huber | Elena Fornari | Anita Morandi | Claudio Maffeis

Pediatric Diabetes and Metabolic Disorders, Department of Surgical Sciences, Dentistry, Paediatrics and Gynaecology, University of Verona, Verona, Italy

Correspondence
Alice Maguolo, Regional Center for Pediatric Diabetes, Pad. 29, Floor 2, Azienda Ospedaliera Universitaria Integrita, Piazzale A. Stefani 1, 37126 Verona, Italy.
Email: alice.maguolo@univr.it

Summary
Increased intestinal permeability has an important role in metabolic dysregulation. In this cross-sectional study, we examined whether serum intestinal permeability marker zonulin and related pro-inflammatory molecules were associated with the oral disposition index, a predictor for the development of type 2 diabetes, in a cohort of children and adolescents with overweight and obesity. Ninety-two children and adolescents were recruited (Male: 43; 12.7 (2.35) years; BMI SDS: 2.7 (0.96)). Anthropometric and clinical parameters, lipid profile, glucose metabolism and plasma levels of zonulin, lipopolysaccharide-binding protein and Interleukin-6 were measured. We found an association between oral disposition index and zonulin ($\beta = -0.243; p = 0.019$) and age ($\beta = -0.307; p = 0.004$), independent of sex and BMI SDS ($R^2 = 0.16; p = 0.005$). Our results show an association between serum zonulin concentration and oral disposition index supporting the hypothesis of increased intestinal permeability as a possible risk factor for glucose metabolism dysregulation in children and adolescents with obesity.

KEYWORDS
children and adolescents, insulin resistance, intestinal permeability, lipopolysaccharide, obesity, type 2 diabetes mellitus, zonulin

1 | BACKGROUND

Obesity is a major risk factor for type 2 diabetes mellitus (T2DM), dyslipidaemia, hypertension and cardiovascular disease.\(^1\) Having obesity in childhood increases the risk of developing T2DM fourfold. Moreover, insulin resistance accompanying obesity plays a key role in the development of diabetes and metabolic syndrome (MetS).\(^1\) A better understanding of the underlying causes of insulin resistance and early identification of children and adolescents with obesity most at risk of metabolic complications is crucial in clinical practice to implement targeted and early preventive strategies.\(^2\) Intestinal permeability has been proposed as one of the main factors involved in the development of insulin resistance.\(^3\) An increased intestinal permeability mediates an altered transit of substances and products, as pro-inflammatory molecules, through the intestinal wall to the systemic circulation, resulting in an alteration of the insulin receptor signalling via multiple pathways.\(^3\) The presence of altered intestinal permeability is not easy to assess and, recently, serum zonulin, a protein produced by the intestinal epithelium that mediates the destruction of enterocytes’ tight junctions, has been proposed as a readily available indicator.\(^4,5\) The aim of this study was to determine whether zonulin and related pro-inflammatory molecules are

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Pediatric Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.

Pediatric Obesity. 2022;17:e12946.
https://doi.org/10.1111/ijpo.12946
associated with the oral disposition index (oDI), as a risk factor for the development of T2DM, in a cohort of children and adolescents with overweight and obesity.

2 METHODS

Ninety-two children and adolescents [Males: 43; mean age 12.7 (2.35) years; BMI SDS: 2.7 (0.96)] were enrolled at the Regional Center for Paediatric Diabetes, University Hospital, Verona (Italy). Inclusion criteria were: European ethnicity, overweight and obesity according to WHO sex and age-specific BMI cut off. Exclusion criteria: genetic or endocrine causes of obesity, type 1 diabetes mellitus or other genetic forms of diabetes, malignancy, associated chronic diseases or chronic pharmacological therapies potentially affecting glucose metabolism, celiac disease or other diseases characterized by malabsorption. None of the children included was affected by T2DM. The protocol was approved by the Institutional Ethics Committee for Clinical Experimentation of Verona and Rovigo (CESC VR-RO) (Italy). Written informed consent was obtained from the children and their parents.

At recruitment, anthropometric and physical evaluation was performed according to standard procedures and data on BMI SDS, waist circumference, Tanner pubertal stage, systolic and diastolic blood pressure (SBP, DBP), as previously described, were collected. Within 15 days from the recruitment visit, patients underwent fasting blood

| Table 1 | Clinical and anthropometric characteristics of the total sample and according to sex |
|---------|-----------------------------------------------------------------------------------|
|          | M (n = 43)                                                             | F (n = 49) | Total (n = 92) | p-value |
| Age (years) | 12.2 (2.2) | 13.2 (2.4) | 12.7 (2.35) | ns |
| Weight (kg)  | 74.8 (23.8) | 82.8 (27.3) | 79.0 (25.92) | ns |
| Height (cm)   | 157.6 (13.5) | 158.2 (10.4) | 157.9 (11.89) | ns |
| BMI (kg/m²)   | 29.4 (6.1) | 32.4 (8.2) | 31.0 (7.43) | ns |
| BMI-SDS       | 2.7 (1.0) | 2.8 (1.0) | 2.7 (0.96) | ns |
| PAS (mmHg)    | 112.6 (14.2) | 113.0 (10.4) | 112.8 (12.2) | ns |
| PAD (mmHg)    | 69.5 (7.5) | 67.4 (7.9) | 68.4 (7.7) | ns |
| Puberty (n = 71) |           |           |                | <0.001 |
| Prepubertal   | 7 (21.2%) | 4 (10.5%) | 11 (15.5%) | ns |
| Pubertal      | 24 (72.2%) | 11 (28.9%) | 35 (49.3%) | ns |
| Postpubertal  | 2 (11.6%) | 23 (60.5%) | 25 (35.2%) | ns |
| TG (mg/dl)    | 86.7 (33.3) | 94.8 (45.8) | 91.1 (40.6) | ns |
| TC (mg/dl)    | 148.6 (29.1) | 151.5 (31.0) | 150.2 (30.0) | ns |
| HDL-c (mg/dl) | 48.3 (8.8) | 44.4 (10.2) | 46.1 (9.7) | ns |
| LDL-c (mg/dl) | 83.0 (28.8) | 88.2 (24.5) | 85.9 (26.4) | ns |
| ALT (U/L)     | 30.9 (13.8) | 25.8 (13.1) | 28.0 (13.5) | ns |
| HbA1C (mmol/mol) | 37.2 (3.4) | 38.2 (4.7) | 37.7 (4.1) | ns |
| Glycaemia (mg/dl) | 95.4 (5.4) | 94.4 (8.2) | 94.9 (7.0) | ns |
| Glycaemia 120' (mg/dl) | 118.2 (20.0) | 116.0 (26.1) | 117.0 (23.3) | ns |
| Insulin (mU/L) | 22.8 (12.9) | 27.4 (16.3) | 25.2 (14.9) | ns |
| HOMA-IR       | 5.0 (3.0) | 6.2 (3.6) | 5.6 (3.4) | ns |
| Matsuda Index | 2.4 (1.5) | 2.1 (1.5) | 2.2 (1.5) | ns |
| IGI           | 3.4 (2.3) | 3.5 (2.3) | 3.5 (2.3) | ns |
| oDI           | 6.3 (3.3) | 5.7 (3.7) | 6.0 (3.5) | ns |
| Zonulina(ng/ml) | 50.2 (6.8) | 50.6 (6.3) | 50.4 (6.5) | ns |
| Ln LBP (ug/ml) | 2.9 (0.3) | 3.0 (0.3) | 2.9 (0.3) | ns |
| Ln IL-6 (pg/ml) | 2.1 (3.6) | 2.5 (4.4) | 2.4 (4.1) | ns |

Notes: Data expressed as number (percentage) or mean (SD). The Student t-test and the Pearson’s chi-squared test for categorical variables were used to test the differences according to sex. Ns. non-significant M vs F.

Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; HbA1c, glycated haemoglobin; HDL-c, high-density lipoprotein cholesterol; HOMA-IR, Homeostatic Model Assessment-insulin resistance; IGI, Insulinogenic Index; IL-6, Interleukin-6; LBP, lipopolysaccharide-binding protein; LDL-c, low-density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver disease; oDI, Oral Disposition Index; PAD, diastolic blood pressure; PAS, systolic blood pressure; SDS, standard deviation score; TC, total cholesterol; TG, triglyceride.
Participants underwent a standard 75 g oral glucose tolerance test (OGTT) after overnight fasting, and the following OGTT-derived indexes were calculated: insulinogenic index (IGI) as $[\text{insulin}_{30}(\text{mU/L}) - \text{insulin}_0(\text{mU/L})] / ([\text{glucose}_{30}(\text{mg/dl}) - \text{glucose}_0(\text{mg/dl})] / \text{insulin}_0(\text{mU/L}))$; Matsuda index as $10,000 / ([\text{Glucose}_0(\text{mg/dl}) \times \text{Insulin}_0(\text{mU/L})] / \text{mean OGTT glucose concentration (mg/dl)} \times (\text{mean OGTT insulin concentration (mU/L)})^{1/2}$; and oral disposition index (oDI) as marker of the adequacy of insulin bioavailability to the prevailing insulin sensitivity given by the formula (Matsuda index $\times$ IGI).8

Plasma levels of zonulin (ng/ml), lipopolysaccharide-binding protein (LBP) (µg/ml), and Interleukin-6 (IL-6) (pg/ml) were measured by ELISA commercial kit (Immundiagnostic K5601, ABNOVA KA0448, and Invitrogen BMS 213HS, respectively). For serum zonulin kit (intra assay CV 6%, inter assay CV 8.3%), according to the manufacturer, a mean value of 34 ng/ml (±14 ng/ml) was declared as normal for healthy persons. The used antibody presents no cross-reactivity against human haptoglobin while the limit of quantitation is 0.183 ng/ml. LBP directly binds lipopolysaccharide (LPS) that belongs exclusively to the Gram-negative bacteria cell wall and is therefore an indicator of intestinal dysbiosis and inflammation, both causes of increased intestinal permeability. IL-6, a proinflammatory cytokine, is an index of the systemic outcomes of elevated intestinal permeability and mediates dysregulating effects on lipid and glucose metabolism. Moreover, IL-6 triggers the transcription of zonulin, promoting the establishment of a vicious cycle that induces increased permeability.3

Kolmogorov–Smirnov test was used to assess the normal distribution of variables. Skewed variables were natural log-transformed to correct for non-Gaussian distribution. The Student’s t-test and the Pearson’s chi-squared test were used to evaluate the differences in clinical and biochemical characteristics according to sex. Linear regression models, adjusted for age, sex and BMI SDS, were applied to test the independent associations between intestinal permeability indices and oDI. A $p$-value <0.05 was considered as statistically significant. All analyses were performed using SPSS v.26.0 (SPSS, Chicago IL).

| Dependent variable | Independent variables | $\beta$ | 95% CIs | $p$ |
|--------------------|-----------------------|--------|--------|-----|
| Oral Disposition Index | Constant | 10.482 | 23.845 | 0.000 |
| | Sex (1 = F) | $-0.008$ | $-1.456$ | $1.343$ | 0.936 |
| | Age (years) | $-0.307$ | $-0.769$ | $0.152$ | 0.980 |
| | BMI SDS | $-0.003$ | $-0.737$ | $0.756$ | 0.980 |
| | Zonulin | $-0.243$ | $-0.240$ | $-0.022$ | 0.019 |

| Dependent variable | Independent variables | $\beta$ | 95% CIs | $p$ |
|--------------------|-----------------------|--------|--------|-----|
| Oral Disposition Index | Constant | 12.936 | 28.181 | 0.000 |
| | Sex (1 = F) | $-0.057$ | $-2.176$ | $1.394$ | 0.663 |
| | Age (years) | $-0.516$ | $-1.205$ | $-0.199$ | 0.007 |
| | BMI SDS | $0.041$ | $-0.755$ | $1.060$ | 0.738 |
| | Pubertal stage | $0.229$ | $-0.812$ | $3.086$ | 0.248 |
| | Zonulin | $-0.262$ | $-0.270$ | $-0.018$ | 0.026 |

Note: Model1: $R^2 = 0.16; p = 0.005$; Model2 ($n = 71$): $R^2 = 0.214; p = 0.008$. Bold indicates significant $p$-values. Abbreviation: BMI-SDS, body mass index–standard deviation score.

### 3 | RESULTS

Ninety-two children and adolescents with overweight and obesity [males = 43; mean age 12.7 (2.35); min-max: 8.5–18 years] and a mean BMI SDS of 2.7 (0.96) were recruited. Anthropometric and metabolic characteristics of the study sample are shown in Table 1. We found a correlation between zonulin and oDI (Pearson $p = -0.256$, value $= 0.015$). Linear regression analysis showed a significant association between BMI SDS and zonulin ($r = 0.233; p = 0.030$), LBP ($r = 0.384; p < 0.001$), and IL-6 ($r = 0.447; p < 0.001$), independent of age and sex. In Table 2, linear regression model revealed an association between oDI and zonulin ($r = -0.243; p = 0.019$) and age ($r = -0.307; p = 0.004$), independent of sex and BMI SDS ($R^2 = 0.16; p = 0.005$). These associations were independent of pubertal stage (Table 2).

### 4 | DISCUSSION

The results of this study show that, among children and adolescents with overweight and obesity, having an increased intestinal permeability estimated by zonulin assay, was associated with a decreased oDI, independent of sex, and BMI SDS. The oDI has been proposed as a reliable predictor of T2DM progression: it reflects the inability of pancreatic beta cells to compensate for insulin resistance, being considered a predictor of conversion to disease as its value decreases.9

Altered intestinal permeability is not easy to assess. The serum zonulin assay has been considered as an easy to perform surrogate marker of dysfunctional intestinal barrier, suitable also in paediatric age.10,11 Zonulin is a protein that reversibly controls intestinal permeability by regulating the binding between the epithelial cells of the intestinal mucosa.4 Intestinal dysbiosis, characteristic of subjects who consume a high-fat and low-fibre diet,12 stimulates the production of zonulin by the lamina propria of the intestinal epithelium.4 Zonulin secretion has been shown to be MyD88-dependent and is followed by an increase in gut permeability secondary to the disassembly of the
zonula occludens-1 from the tight junctional complex. Activation of the zonulin pathway may represent a defensive mechanism that “flushes out” microorganisms, contributing to the host’s innate immune response against changes in the microbiome ecosystem (small intestinal bacterial growth and/or dysbiosis). The increased intestinal permeability leads to the translocation of bacterial substances, as LPS, and products of their metabolism, as short-chain fatty acids, in the systemic circulation, eventually determining a low-grade inflammatory status, also called endotoxemia that leads to metabolic dysregulation.

The association between altered intestinal permeability and impaired glucose metabolism was reported by Vangipurapu et al. who found an association between several microbial metabolites related to the gut microbiota, passed into circulation due to leaks in the intestinal barrier, with an increased risk of incident type 2 diabetes in adults. Accordingly, a negative correlation between circulating indolepropionic Acid, a microbial metabolite of tryptophan, and the onset of T2DM was found in a 1-year follow-up of subjects with impaired glucose tolerance. Pacifico et al. showed a positive association between serum zonulin and NAFLD, and a negative association between zonulin and whole-body insulin sensitivity index. Similarly, Kume et al. and Kim et al. showed a positive correlation between serum zonulin and levels of insulin resistance and BMI SDS in groups of children and adolescents with obesity.

The new contribution of our study consists in demonstrating for the first time an association between zonulin and oDI, that is, a risk factor for the development of T2DM, independent of the level of obesity. Therefore, zonulin could be proposed not just as a marker of altered intestinal permeability in children and adolescents with overweight and obesity but also as a possible indicator of metabolism dysregulation helping to identify patients at increased risk of developing T2DM worthy of early and targeted preventive and therapeutic interventions.

Moreover, our findings sustain the central role of dysbiosis and intestinal permeability in early glucose metabolism dysregulation of obesity. The control of dysbiosis may contribute to improve glucose metabolism in obesity. Changes in dietary habits consisting of a reduction in fat and an increase in fibre intake induce a significant decrease in intestinal permeability, also independent of a decrease in BMI. Accordingly, in a cross-sectional study, the use of inulin-enriched pasta induced a reduction in circulating zonulin levels. Finally, in addition to diet, intake of prebiotics or probiotics could also improve dysbiosis and consequently reduce intestinal permeability in patients with obesity.

Our study has some limitations: i) the sample size is quite small; ii) the cross-sectional design does not allow to explore causality; iii) unavailability of data on diet that has an important influence on the microbiota and consequently on intestinal permeability; iv) the absence of measures of adiposity to be included in the model and v) the absence of normal-weight subjects that could further clarify the independence of the relationship between zonulin and oDI from BMI SDS.

To conclude, our study is the first to demonstrate that, among children and adolescents with overweight and obesity, having increased serum zonulin levels (i.e. a plausible marker of altered intestinal permeability) is associated with an increased risk of potential progression to T2DM, independent of sex and BMI SDS.

ACKNOWLEDGEMENTS
CM designed the study; MC carried out experiments; FO, AMa, CZ and VH researched and analysed the data. FO, AMa and VH co-wrote the manuscript. CM, AMa, FO, CZ, EF and AMo discussed and edited the manuscript. All authors were involved had final approval of the submitted and published versions. Open Access Funding provided by Universita degli Studi di Verona within the CRUI-CARE Agreement.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

ORCID
Alice Maguolo https://orcid.org/0000-0002-8921-2012
Claudio Maffeis https://orcid.org/0000-0002-3563-4404

REFERENCES
1. Bjerregaard LG, Jensen BW, Ängquist L, Osler M, Sørensen TIA, Baker JL. Change in overweight from childhood to early adulthood and risk of type 2 diabetes. N Engl J Med. 2018;378(14):1302-1312. doi:10.1056/NEJMoa1713231
2. Ellis LJ, Rees K, Brown T, et al. Interventions for treating children and adolescents with overweight and obesity: an overview of Cochrane reviews. Int J Obes (Lond). 2018;42(11):1823-1833. doi:10.1038/s41366-018-0230-y
3. Caricilli A, Saad M. The role of gut microbiota on insulin resistance. Nutrients. 2013;5(3):829-851. doi:10.3390/nu5030829
4. REA, Panigrahi P, Bamford P, et al. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology. 2002;123(5):1607-1615. doi:10.1053/GAST.2002.36578
5. Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases [version 1; peer review: 3 approved]. F1000Research. 2020;9:69. doi:10.12688/F1000RESEARCH.20510.1
6. De Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007;85(9):660-667. doi:10.2471/BLT.04.043497
7. Maguolo A, Olivieri F, Zusi C, Miraglia Del Giudice E, Morandi A, Maffeis C. The risk of metabolic derangements is higher in children and adolescents with overweight or obesity born small for gestational age. Nutr Metab Cardiovasc Dis. 2021;31(6):1903-1910. doi:10.1016/j.numecd.2021.02.025
8. Olivieri F, Zusi C, Morandi A, et al. “IGT-like” status in normoglycemia tolerant obese children and adolescents: the additive role of glucose profile morphology and 2-hours glucose concentration during the oral glucose tolerance test. Int J Obes (Lond). 2019;43(7):1363-1369. doi:10.1038/s41366-018-0297-5
9. Caprio S. The oral disposition index: a valuable estimate of IGT-like function in obese youth. J Pediatr. 2012;161(1):3-4. doi:10.1016/j.jpeds.2012.02.013
10. Cortez APB, Fisberg M, Morais MB. Intestinal permeability and small intestine bacterial overgrowth in excess weight adolescents. Pediatr Obes. 2021;16(5):e12741. doi:10.1111/ipob.12741
11. Sapone A, de Magistris L, Pietzak M, et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. *Diabetes*. 2006;55(5):1443-1449. doi:10.2337/db05-1593

12. Martina A, Felis GE, Corradi M, Maffeis C, Torriani S, Venema K. Effects of functional pasta ingredients on different gut microbiota as revealed by TIM-2 in vitro model of the proximal colon. *Benef Microbes*. 2019;10(3):301-313. doi:10.3920/BM2018.0088

13. Vangipurapu J, Silva LF, Kuulasmaa T, Smith U, Laakso M. Microbiota-related metabolites and the risk of type 2 diabetes. *Diabetes Care*. 2020;43(6):1319-1325. doi:10.2337/dc19-2533

14. Tuomainen M, Lindström J, Lehtonen M, et al. Associations of serum indolepropionic acid, a gut microbiota metabolite, with type 2 diabetes and low-grade inflammation in high-risk individuals. *Nutr Diabetes*. 2018;8:35. doi:10.1038/s41387-018-0046-9

15. Pacifico L. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease. *World J Gastroenterol*. 2014;20(45):17107-17114. doi:10.3748/wjg.v20.i45.17107

16. Küme T, Acar S, Tuhan H, et al. The relationship between serum zonulin level and clinical and laboratory parameters of childhood obesity. *JCRPE J Clin Res Pediatr Endocrinol*. 2017;9(1):31-38. doi:10.4274/jcrpe.3682

17. Kim JH, Heo JS, Baek KS, et al. Zonulin level, a marker of intestinal permeability, is increased in association with liver enzymes in young adolescents. *Clin Chim Acta*. 2018;481(March):218-224. doi:10.1016/j.cca.2018.03.005

18. Rainone V, Schneider L, Saullie I, et al. Upregulation of inflammasome activity and increased gut permeability are associated with obesity in children and adolescents. *Int J Obes (Lond)*. 2016;40(6):1026-1033. doi:10.1038/ijo.2016.26

19. Russo F, Linsalata M, Clemente C, et al. Inulin-enriched pasta improves intestinal permeability and modifies the circulating levels of zonulin and glucagon-like peptide 2 in healthy young volunteers. *Nutr Res*. 2012;32:940-946. doi:10.1016/j.nutres.2012.09.010

20. Sabatino A, Regolisti G, Cosola C, Gesualdo L, Fiaccadori E. Intestinal microbiota in type 2 diabetes and chronic kidney disease. *Curr Diab Rep*. 2017;17(3):16. doi:10.1007/s11892-017-0841-z

**How to cite this article:** Olivieri F, Maguolo A, Corradi M, et al. Serum zonulin as an index of glucose dysregulation in children and adolescents with overweight and obesity. *Pediatric Obesity*. 2022;17(10):e12946. doi:10.1111/ijpo.12946